Castle Biosciences has announced that study results of a proprietary predictive test for esophageal cancer demonstrated strong accuracy and specificity in identifying patients who are likely to have tumors that are extremely resistant to standard pre-surgical treatment of chemotherapy and radiation. Data from this second validation study were presented in San Francisco at the 2014 Gastrointestinal Cancers Symposium sponsored by the American Society of Clinical Oncology.
More...
More...